Cerevel Therapeutics is a biopharmaceutical company working relentlessly to unravel the mysteries of the brain to treat neuroscience diseases.
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $125M
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
| - | Ally Bridg... | ally-bridg... |
| - | Bain Capit... | baincapita... |
| 28.05.2024 | Bain Capit... | baincapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.04.2021 | - | $125M | - |
Mentions in press and media 15
| Date | Title | Description |
| 24.12.2025 | Syremis Therapeutics Launches With $165 Million Series A Funding To Advance New Schizophrenia And Depression Drug Programs | Syremis Therapeutics, a clinical-stage biopharmaceutical company focused on mental health, has launched with $165 million in Series A financing to advance a neuropsychiatric pipeline rooted in clinically validated biology. The round was co-... |
| 19.12.2025 | Syremis Therapeutics Raises $165M in Series A Financing | Syremis Therapeutics, a Tel Aviv, Israel, and Boston, Massachusetts-based clinical-stage biopharmaceutical company developing novel medicines for the treatment of mental health, launched with $165m Series A financing. The round was co-led b... |
| 18.06.2025 | The Dawn of Radioligand Therapies: A New Era in Precision Oncology | In the realm of cancer treatment, innovation is the lifeblood that fuels hope. The latest beacon of this hope shines brightly on radioligand therapies (RLTs). These therapies are not just a whisper of potential; they are a clarion call for ... |
| 13.06.2025 | Indianapolis-based startup leans on connections to treat brain diseases | Please subscribe to IBJ to decode this article. so" co7tniifn:wct=l l5m=/nne4bBc_omtI"/ioaedel"-_oii=ii0-edidC5a2ru["00-mca5ae=fud othmtwi1ga"e"3r"daletl0ca]nsene d vy.sdstiheip =loto jee6teo mpts m3t [c6i... |
| 07.10.2024 | Kailera Therapeutics: $400 Million (Series A) Raised To Advance Next-Gen Therapies For Obesity | Kailera Therapeutics announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for treating obesity and related conditions. And Kailera launches with a $400 million... |
| 11.10.2023 | Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock | - |
| 13.12.2021 | PHYSICIAN AND SCIENTIST, SERGE PRZEDBORSKI, JOINS LUCIOLE PHARMACEUTICALS' SCIENCE ADVISORY BOARD | NATICK, Mass., Dec. 13, 2021 /PRNewswire/ -- Luciole Pharmaceuticals, Inc is pleased to announce that Serge Przedborski, MD, Ph.D., is joining the company's scientific advisory board. Dr. Przedborski, is the Page and William Black Professor... |
| 02.07.2021 | Cerevel Therapeutics : Announces Pricing of $350 Million Public Offering of Common Stock (Form 8-K) | Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock CAMBRIDGE, Mass., July 1, 2021 (GLOBE NEWSWIRE) - Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to tr... |
| 02.07.2021 | Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock | CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced un... |
| 13.04.2021 | Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon | Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson’s disease through planned NDA submission Data readouts from tavapadon Phase 3 TEMPO program expected beginning i... |
Show more